MASSARI, FRANCESCO
MASSARI, FRANCESCO
DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE
Ricercatori a tempo determinato
2-weekly docetaxel: issues for clinical practice
2015 Massari F.; Maines F.; Bria E.; Galligioni E.; Caffo O.; Tortora G.
2015 and human cancer: Back to overall survival
2016 Ciccarese C.; Massari F.; Tortora G.
223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience.
2018 Boni G, Mazzarri S, Cianci C, Galli L, Farnesi A, Borsatti E, Bortolus R, Fratino L, Gobitti C, Lamaj E, Ghedini P, Rizzini EL, Massari F, Dionisi V, Fanti S, Volterrani D, Monari F.
A brand-new CAR for macrophages: Is it time to fire up the engines of a new era for the treatment of renal cell carcinoma?
2021 Massari F.; Rizzo A.; Mollica V.; Santoni M.
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor.
2018 Mollica V, Di Nunno V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy
2022 Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss.
2019 Di Nunno V, Mollica V, Brunelli M, Gatto L, Schiavina R, Fiorentino M, Santoni M, Montironi R, Caliò A, Eccher A, Milella M, Martignoni G, Brunocilla E, Massari F
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents
2022 Rizzo A.; Oderda M.; Mollica V.; Merler S.; Morelli F.; Fragomeno B.; Taveri E.; Sorgentoni G.; Santoni M.; Massari F.
A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34
2021 Ricci C.; Franceschini T.; Giunchi F.; Borsato M.; Mollica V.; Massari F.; Fiorentino M.
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: A case report
2015 Ciccarese C.; Ferrara R.; Fantinel E.; Zecchetto C.; Simionato F.; Grego E.; Ortolani S.; Caccese M.; Bimbatti D.; Cingarlini S.; Brunelli M.; Andreini A.; Tortora G.; Massari F.
Acquired hemophagocytic syndrome: Comment to the case report
2015 Ciccarese C.; Massari F.; Tortora G.
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets
2017 Cimadamore A.; Scarpelli M.; Piva F.; Massari F.; Gasparrini S.; Doria A.; Cheng L.; Lopez-Beltran A.; Montironi R.
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer
2023 Nuvola, Giacomo; Santoni, Matteo; Rizzo, Mimma; Rosellini, Matteo; Mollica, Veronica; Rizzo, Alessandro; Marchetti, Andrea; Battelli, Nicola; Massari, Francesco
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study
2021 Massari, Francesco; Di Nunno, Vincenzo; Guida, Annalisa; Costa Silva, Carolina Alves; Derosa, Lisa; Mollica, Veronica; Colomba, Emeline; Brandi, Giovanni; Albiges, Laurence
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study
2021 Massari F.; Di Nunno V.; Guida A.; Costa Silva C.A.; Derosa L.; Mollica V.; Colomba E.; Brandi G.; Albiges L.
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies
2017 Ciccarese C.; Iacovelli R.; Brunelli M.; Massari F.; Bimbatti D.; Fantinel E.; De Marco V.; Porcaro A.B.; Martignoni G.; Artibani W.; Tortora G.
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials
2016 Massari F.; Modena A.; Ciccarese C.; Pilotto S.; Maines F.; Bracarda S.; Sperduti I.; Giannarelli D.; Carlini P.; Santini D.; Tortora G.; Porta C.; Bria E.
Adenocarcinoma of the paraurethral glands: A case report
2014 Massari F.; Ciccarese C.; Modena A.; Maines F.; Segala D.; Luchini C.; Marcolini L.; Cavicchioli F.; Cavalleri S.; Bria E.; Brunelli M.; Martignoni G.; Artibani W.; Tortora G.
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies
2018 Massari F.; Santoni M.; di Nunno V.; Cheng L.; Lopez-Beltran A.; Cimadamore A.; Gasparrini S.; Scarpelli M.; Battelli N.; Montironi R.
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
2022 Pal S.K.; Uzzo R.; Karam J.A.; Master V.A.; Donskov F.; Suarez C.; Albiges L.; Rini B.; Tomita Y.; Kann A.G.; Procopio G.; Massari F.; Zibelman M.; Antonyan I.; Huseni M.; Basu D.; Ci B.; Leung W.; Khan O.; Dubey S.; Bex A.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| 2-weekly docetaxel: issues for clinical practice | Massari F.; Maines F.; Bria E.; Galligioni E.; Caffo O.; Tortora G. | 2015-01-01 | CANCER BIOLOGY & THERAPY | - | 1.01 Articolo in rivista | - |
| 2015 and human cancer: Back to overall survival | Ciccarese C.; Massari F.; Tortora G. | 2016-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| 223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. | Boni G, Mazzarri S, Cianci C, Galli L, Farnesi A, Borsatti E, Bortolus R, Fratino L, Gobitti C, L...amaj E, Ghedini P, Rizzini EL, Massari F, Dionisi V, Fanti S, Volterrani D, Monari F. | 2018-01-01 | TUMORI | - | 1.01 Articolo in rivista | - |
| A brand-new CAR for macrophages: Is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? | Massari F.; Rizzo A.; Mollica V.; Santoni M. | 2021-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. | Mollica V, Di Nunno V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E,... Ardizzoni A, Massari F | 2018-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |
| A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy | Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa...; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco | 2022-01-01 | PATHOLOGY RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
| A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. | Di Nunno V, Mollica V, Brunelli M, Gatto L, Schiavina R, Fiorentino M, Santoni M, Montironi R, Ca...liò A, Eccher A, Milella M, Martignoni G, Brunocilla E, Massari F | 2019-01-01 | MOLECULAR DIAGNOSIS & THERAPY | - | 1.01 Articolo in rivista | - |
| A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents | Rizzo A.; Oderda M.; Mollica V.; Merler S.; Morelli F.; Fragomeno B.; Taveri E.; Sorgentoni G.; S...antoni M.; Massari F. | 2022-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |
| A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34 | Ricci C.; Franceschini T.; Giunchi F.; Borsato M.; Mollica V.; Massari F.; Fiorentino M. | 2021-01-01 | PATHOLOGY RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
| Acquired hemophagocytic syndrome in a patient with synovial sarcoma: A case report | Ciccarese C.; Ferrara R.; Fantinel E.; Zecchetto C.; Simionato F.; Grego E.; Ortolani S.; Caccese... M.; Bimbatti D.; Cingarlini S.; Brunelli M.; Andreini A.; Tortora G.; Massari F. | 2015-01-01 | FUTURE SCIENCE OA | - | 1.01 Articolo in rivista | - |
| Acquired hemophagocytic syndrome: Comment to the case report | Ciccarese C.; Massari F.; Tortora G. | 2015-01-01 | FUTURE SCIENCE OA | - | 1.01 Articolo in rivista | - |
| Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets | Cimadamore A.; Scarpelli M.; Piva F.; Massari F.; Gasparrini S.; Doria A.; Cheng L.; Lopez-Beltra...n A.; Montironi R. | 2017-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer | Nuvola, Giacomo; Santoni, Matteo; Rizzo, Mimma; Rosellini, Matteo; Mollica, Veronica; Rizzo, Ales...sandro; Marchetti, Andrea; Battelli, Nicola; Massari, Francesco | 2023-01-01 | EXPERT REVIEW OF ANTICANCER THERAPY | - | 1.01 Articolo in rivista | - |
| Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study | Massari, Francesco; Di Nunno, Vincenzo; Guida, Annalisa; Costa Silva, Carolina Alves; Derosa, Lis...a; Mollica, Veronica; Colomba, Emeline; Brandi, Giovanni; Albiges, Laurence | 2021-01-01 | CLINICAL GENITOURINARY CANCER | - | 1.01 Articolo in rivista | - |
| Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study | Massari F.; Di Nunno V.; Guida A.; Costa Silva C.A.; Derosa L.; Mollica V.; Colomba E.; Brandi G....; Albiges L. | 2021-01-01 | CLINICAL GENITOURINARY CANCER | - | 1.01 Articolo in rivista | - |
| Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies | Ciccarese C.; Iacovelli R.; Brunelli M.; Massari F.; Bimbatti D.; Fantinel E.; De Marco V.; Porca...ro A.B.; Martignoni G.; Artibani W.; Tortora G. | 2017-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials | Massari F.; Modena A.; Ciccarese C.; Pilotto S.; Maines F.; Bracarda S.; Sperduti I.; Giannarelli... D.; Carlini P.; Santini D.; Tortora G.; Porta C.; Bria E. | 2016-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Adenocarcinoma of the paraurethral glands: A case report | Massari F.; Ciccarese C.; Modena A.; Maines F.; Segala D.; Luchini C.; Marcolini L.; Cavicchioli ...F.; Cavalleri S.; Bria E.; Brunelli M.; Martignoni G.; Artibani W.; Tortora G. | 2014-01-01 | HISTOLOGY AND HISTOPATHOLOGY | - | 1.01 Articolo in rivista | - |
| Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies | Massari F.; Santoni M.; di Nunno V.; Cheng L.; Lopez-Beltran A.; Cimadamore A.; Gasparrini S.; Sc...arpelli M.; Battelli N.; Montironi R. | 2018-01-01 | CANCER TREATMENT REVIEWS | - | 1.01 Articolo in rivista | - |
| Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial | Pal S.K.; Uzzo R.; Karam J.A.; Master V.A.; Donskov F.; Suarez C.; Albiges L.; Rini B.; Tomita Y....; Kann A.G.; Procopio G.; Massari F.; Zibelman M.; Antonyan I.; Huseni M.; Basu D.; Ci B.; Leung W.; Khan O.; Dubey S.; Bex A. | 2022-01-01 | THE LANCET | - | 1.01 Articolo in rivista | - |